Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.

Parunov LA, Soshitova NP, Fadeeva OA, Balandina AN, Kopylov KG, Kumskova MA, Gilbert JC, Schaub RG, McGinness KE, Ataullakhanov FI, Panteleev MA.

Thromb Res. 2014 Jan;133(1):112-9. doi: 10.1016/j.thromres.2013.10.036. Epub 2013 Nov 1.

PMID:
24263002
2.

Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation.

Parunov LA, Fadeeva OA, Balandina AN, Soshitova NP, Kopylov KG, Kumskova MA, Gilbert JC, Schaub RG, McGinness KE, Ataullakhanov FI, Panteleev MA.

J Thromb Haemost. 2011 Sep;9(9):1825-34. doi: 10.1111/j.1538-7836.2011.04412.x.

3.

Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.

Gissel M, Orfeo T, Foley JH, Butenas S.

Thromb Res. 2012 Dec;130(6):948-55. doi: 10.1016/j.thromres.2012.08.299. Epub 2012 Aug 27.

4.

Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.

Chang JY, Chantrathammachart P, Monroe DM, Key NS.

Thromb Res. 2012 Sep;130(3):e151-7. doi: 10.1016/j.thromres.2012.05.010. Epub 2012 May 30.

PMID:
22658294
5.

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.

Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, Kurz JC, McGinness KE.

Blood. 2011 May 19;117(20):5514-22. doi: 10.1182/blood-2010-10-311936. Epub 2011 Mar 9.

6.

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.

Gorczyca ME, Nair SC, Jilma B, Priya S, Male C, Reitter S, Knoebl P, Gilbert JC, Schaub RG, Dockal M, McGinness KE, Pabinger I, Srivastava A.

J Thromb Haemost. 2012 Aug;10(8):1581-90. doi: 10.1111/j.1538-7836.2012.04790.x.

7.

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.

Hilden I, Lauritzen B, Sørensen BB, Clausen JT, Jespersgaard C, Krogh BO, Bowler AN, Breinholt J, Gruhler A, Svensson LA, Petersen HH, Petersen LC, Balling KW, Hansen L, Hermit MB, Egebjerg T, Friederichsen B, Ezban M, Bjørn SE.

Blood. 2012 Jun 14;119(24):5871-8. doi: 10.1182/blood-2012-01-401620. Epub 2012 May 4.

8.

Hemostatic properties of a TFPI antibody.

Petersen LC.

Thromb Res. 2012 May;129 Suppl 2:S44-5. doi: 10.1016/j.thromres.2012.02.030. Epub 2012 Mar 8. Review.

PMID:
22405586
9.

The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.

He S, Blombäck M, Jacobsson Ekman G, Hedner U.

J Thromb Haemost. 2003 Jun;1(6):1215-9.

10.

Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.

Knappe S, Gorczyca ME, Jilma B, Derhaschnig U, Hartmann R, Palige M, Scheiflinger F, Dockal M.

Thromb Haemost. 2013 Mar;109(3):450-7. doi: 10.1160/TH12-07-0529. Epub 2013 Jan 24.

PMID:
23348798
11.

Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.

Radtke KP, Griffin JH, Riceberg J, Gale AJ.

J Thromb Haemost. 2007 Jan;5(1):102-8. Epub 2006 Oct 24.

12.

Effect of factor VIII on tissue factor-initiated spatial clot growth.

Ovanesov MV, Lopatina EG, Saenko EL, Ananyeva NM, Ul'yanova LI, Plyushch OP, Butilin AA, Ataullakhanov FI.

Thromb Haemost. 2003 Feb;89(2):235-42.

PMID:
12574801
13.

Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.

Hvas AM, Sørensen HT, Norengaard L, Christiansen K, Ingerslev J, Sørensen B.

J Thromb Haemost. 2007 Dec;5(12):2408-14. Epub 2007 Sep 6.

14.

Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein.

Waters EK, Genga RM, Thomson HA, Kurz JC, Schaub RG, Scheiflinger F, McGinness KE.

J Thromb Haemost. 2013 Jun;11(6):1137-45. doi: 10.1111/jth.12201.

15.

Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A.

Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O.

Blood Coagul Fibrinolysis. 1995 Jul;6(5):388-94.

PMID:
8589204
16.

Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.

Peters RT, Toby G, Lu Q, Liu T, Kulman JD, Low SC, Bitonti AJ, Pierce GF.

J Thromb Haemost. 2013 Jan;11(1):132-41. doi: 10.1111/jth.12076.

17.

Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.

Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JC, Nieuwenhuis HK, de Groot PG.

Blood. 2002 Jan 1;99(1):175-9.

18.

Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.

Bassus S, Wegert W, Krause M, Escuriola-Ettinghausen C, Siegemund A, Petros S, Scholz T, Scharrer I, Kreuz W, Engelmann L, Kirchmaier CM.

Platelets. 2006 Sep;17(6):378-84.

PMID:
16973498
19.

Turoctocog alfa for the treatment of hemophilia A.

Haddley K.

Drugs Today (Barc). 2014 Feb;50(2):121-31. doi: 10.1358/dot.2014.50.2.2116671. Review.

PMID:
24619589
20.

Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.

Doshi BS, Gangadharan B, Doering CB, Meeks SL.

PLoS One. 2012;7(10):e48172. doi: 10.1371/journal.pone.0048172. Epub 2012 Oct 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk